Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Xeris Biopharma HoldingsXERS +3.45%71 Days Inventory is 616.62 as of Mar. 2026, which is 52% above its 10-year median of 405.03. GuruFocus rates XERS with a GF Score™ of 71/100 and a GF Value™ of $5.20 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 923 Drug Manufacturers companies, Xeris Biopharma Holdings ranks worse than 95.77% on this metric.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Xeris Biopharma Holdings's Inventory Turnover for the
three
months ended in Mar. 2026 was 0.15.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Xeris Biopharma Holdings's Inventory-to-Revenue for the
three
months ended in Mar. 2026 was 0.86.
Xeris Biopharma Holdings (NAS:XERS) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Xeris Biopharma Holdings's Inventory Turnover for the
three
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Xeris Biopharma Holdings's Inventory to Revenue for the
three
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Xeris Biopharma Holdings Days Inventory Related Terms
Xeris Biopharma Holdings Days Inventory Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XERS vs PAHC, PRGO, ALVO: Days Inventory Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Xeris Biopharma Holdings's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xeris Biopharma Holdings Days Inventory vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Xeris Biopharma Holdings's Days Inventory distribution charts can be found below:
* The bar in red indicates where Xeris Biopharma Holdings's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xeris Biopharma Holdings (XERS) has a Days Inventory of 616.62 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Xeris Biopharma Holdings and its competitors. This is 52% above median its historical median of 405.03. Over the past decade, Xeris Biopharma Holdings' Days Inventory has ranged from 206.00 to 542.94. According to the industry distribution chart, Xeris Biopharma Holdings ranks #884 out of 923 companies in the Drug Manufacturers industry, placing it in the top 95.8%.
Is Xeris Biopharma Holdings' Days Inventory too high?
Xeris Biopharma Holdings' current Days Inventory of 616.62 is 52% above median its 10-year median of 405.03. Over the past 10 years, this metric has ranged from a low of 206.00 to a high of 542.94. The Drug Manufacturers industry median Days Inventory is 164.38. Xeris Biopharma Holdings' value of 616.62 is 275.1% above this industry median. Based on the distribution chart, Xeris Biopharma Holdings ranks #884 out of 923 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Xeris Biopharma Holdings has a GF Score™ of 71/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Xeris Biopharma Holdings' Days Inventory compare to PAHC and PRGO?
According to the Drug Manufacturers industry distribution chart, Xeris Biopharma Holdings ranks #884 out of 923 companies for Days Inventory. This places Xeris Biopharma Holdings in the lower half of its industry. The industry median Days Inventory is 164.38. Xeris Biopharma Holdings' value of 616.62 is 275.1% above this benchmark. Historically, Xeris Biopharma Holdings' own Days Inventory has ranged from 206.00 to 542.94 over the past decade. While the company's 10-year median is 405.03 vs. the industry median of 164.38, Xeris Biopharma Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Drug Manufacturers company?
The median Days Inventory among Drug Manufacturers companies is 164.38, based on 923 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Xeris Biopharma Holdings's current Days Inventory of 616.62 is 275.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Xeris Biopharma Holdings and its competitors. For the Drug Manufacturers industry, the median Days Inventory is 164.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Xeris Biopharma Holdings's current Days Inventory is 616.62, which is 52% above median its own 10-year median of 405.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xeris Biopharma Holdings stock overvalued right now?
Based on GuruFocus' analysis, Xeris Biopharma Holdings (XERS) is currently considered Significantly Overvalued. The stock's GF Value™ is $5.20, compared to a current price of $8.56 — trading 64.5% above its estimated fair value. The current Days Inventory is 616.62, which is 52% above median its 10-year median of 405.03 and 275.1% above the Drug Manufacturers industry median of 164.38. Xeris Biopharma Holdings' overall GF Score™ is 71/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Xeris Biopharma Holdings (XERS), the current Days Inventory is 616.62 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Xeris Biopharma Holdings (XERS) Overvalued in 2026?
Based on GuruFocus' analysis, Xeris Biopharma Holdings stock appears to be overvalued.
The current stock price of $8.56 is trading 64.5% above its estimated GF Value™ of $5.20.
GuruFocus considers Xeris Biopharma Holdings to be Significantly Overvalued.
Key valuation signals for XERS:
Days Inventory: 616.62 (52% above median its 10-year median of 405.03)
GF Value™: $5.20 vs. price of $8.56 (64.5% above fair value)
Industry Position: 275.1% above the Drug Manufacturers median (#884 of 923)
No single metric tells the full story. See the XERS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.
71GF Score
Get the complete analysis for XERS
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XERS has been successfully added to your 
